Crescendo Biologics announces clinical biodistribution data of Humabody® bispecific CB307 at ESMO 2024
Press Releases
26 June 2024
Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis
10 April 2024
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024
06 March 2024
Crescendo Biologics to present at the 2024 AACR Annual Meeting
29 February 2024
Crescendo Biologics to participate in upcoming investor and partnering conferences
09 February 2024
Crescendo Biologics announces publication in Neoplasia of preclinical tumour penetration data supporting CB307